Frederick J. Kohlhapp

3.4k total citations · 1 hit paper
27 papers, 2.3k citations indexed

About

Frederick J. Kohlhapp is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Frederick J. Kohlhapp has authored 27 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 14 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Frederick J. Kohlhapp's work include CAR-T cell therapy research (12 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (10 papers). Frederick J. Kohlhapp is often cited by papers focused on CAR-T cell therapy research (12 papers), Immunotherapy and Immune Responses (12 papers) and Immune Cell Function and Interaction (10 papers). Frederick J. Kohlhapp collaborates with scholars based in United States, Netherlands and Croatia. Frederick J. Kohlhapp's co-authors include Howard L. Kaufman, Andrew Zloza, Marcus E. Peter, Arnab Mitra, Ernst Lengyel, Jason M. Schenkel, Jai S. Rudra, Erica Huelsmann, José A. Guevara-Patiño and Charles B. Chesson and has published in prestigious journals such as Nature Medicine, Nature Communications and The Journal of Immunology.

In The Last Decade

Frederick J. Kohlhapp

27 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic viruses: a new class of immunotherapy drugs

2015 1.2k citations Howard L. Kaufman, Frederick J. Kohlhapp et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Frederick J. Kohlhapp

Since Specialization

Citations

This map shows the geographic impact of Frederick J. Kohlhapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick J. Kohlhapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick J. Kohlhapp more than expected).

Fields of papers citing papers by Frederick J. Kohlhapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick J. Kohlhapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick J. Kohlhapp. The network helps show where Frederick J. Kohlhapp may publish in the future.

Co-authorship network of co-authors of Frederick J. Kohlhapp

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick J. Kohlhapp. A scholar is included among the top collaborators of Frederick J. Kohlhapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick J. Kohlhapp. Frederick J. Kohlhapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NKG2D signaling shifts the balance of CD8 T cells from single cytokine- to polycytokine-producing effector cells 2023 ·Molecular Immunology ·Frederick J. Kohlhapp, Jeremy A. O’Sullivan, Tamson V. Moore, Andrew Zloza, José A. Guevara-Patiño	6
2	Memory Precursors and Short-Lived Effector T cell Subsets Have Different Sensitivities to TGFβ 2023 ·International Journal of Molecular Sciences ·Jeremy A. O’Sullivan, Frederick J. Kohlhapp, Andrew Zloza, (unknown), Brianna Burke, Nickolai O. Dulin, José A. Guevara-Patiño	1
3	Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine Model 2022 ·Diagnostics ·Marco Rossi, (unknown), Frederick J. Kohlhapp, Jenna H. Newman, (unknown), (unknown), (unknown), (unknown), Robert Donnelly, Timothy M. Kuzel, Jochen Reiser, José A. Guevara-Patiño, Andrew Zloza	4
4	Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies 2017 ·Frontiers in Oncology ·Sachin R. Jhawar, (unknown), Praveen K. Bommareddy, (unknown), Frederick J. Kohlhapp, Sharad Goyal, Jason M. Schenkel, Ann W. Silk, Andrew Zloza	130
5	Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma 2016 ·Cancer Immunology Immunotherapy ·Andrew Zloza, (unknown), Erica Huelsmann, (unknown), Tasha M. Hughes, Frederick J. Kohlhapp, Howard L. Kaufman	9
6	MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment 2015 ·Oncogene ·Frederick J. Kohlhapp, Arnab Mitra, Ernst Lengyel, Marcus E. Peter	166
7	Oncolytic viruses: a new class of immunotherapy drugs breakdown → 2015 ·Nature Reviews Drug Discovery ·Howard L. Kaufman, Frederick J. Kohlhapp, Andrew Zloza	1194
8	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade 2015 ·Journal for ImmunoTherapy of Cancer ·Frederick J. Kohlhapp, (unknown), Tasha M. Hughes, Erica Huelsmann, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Arman Nabatiyan, Carl E. Ruby, (unknown), Jai S. Rudra, Jason M. Schenkel, David Masopust, Andrew Zloza, Howard L. Kaufman	45
9	Talimogene laherparepvec (T-VEC) as cancer immunotherapy 2015 ·Drugs of today ·Frederick J. Kohlhapp, Andrew Zloza, Howard L. Kaufman	29
10	Single-step nanoparticle antigen presentation system for tumor immunotherapy 2015 ·Journal for ImmunoTherapy of Cancer ·Frederick J. Kohlhapp, Erica Huelsmann, Jai S. Rudra, Arman Nabatiyan, Andrew Zloza	2
11	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with CTLA-4 blockade and IL-2 (TUM2P.1039) 2015 ·The Journal of Immunology ·Frederick J. Kohlhapp, (unknown), Tasha M. Hughes, Erica Huelsmann, Andrew Zloza, Howard L. Kaufman	1
12	Enhancing the Magnitude of Antibody Responses through Biomaterial Stereochemistry 2015 ·ACS Biomaterials Science & Engineering ·Rajagopal Appavu, Charles B. Chesson, Alexey Y. Koyfman, (unknown), Frederick J. Kohlhapp, Andrew Zloza, Jai S. Rudra	42
13	CD95 and CD95L promote and protect cancer stem cells 2014 ·Nature Communications ·Paolo Ceppi, (unknown), Frederick J. Kohlhapp, Abhinandan Pattanayak, Annika Hau, Xia Liu, Huiping Liu, Andrea E. Murmann, Marcus E. Peter	66
14	Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses 2013 ·Vaccine ·Charles B. Chesson, Erica Huelsmann, (unknown), Frederick J. Kohlhapp, (unknown), Arman Nabatiyan, Andrew Zloza, Jai S. Rudra	70
15	NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses 2012 ·Nature Medicine ·Andrew Zloza, Frederick J. Kohlhapp, Gretchen E. Lyons, Jason M. Schenkel, Tamson V. Moore, (unknown), Jeremy A. O’Sullivan, Vineeth Varanasi, Jesse W. Williams, (unknown), Emily Bellavance, Amanda L. Marzo, Paul G. Thomas, Biljana Zafirova, Bojan Polić, Lena Al‐Harthi, Anne I. Sperling, José A. Guevara-Patiño	49
16	CD8+ T Cells Sabotage Their Own Memory Potential through IFN-γ–Dependent Modification of the IL-12/IL-15 Receptor α Axis on Dendritic Cells 2012 ·The Journal of Immunology ·Frederick J. Kohlhapp, Andrew Zloza, Jeremy A. O’Sullivan, Tamson V. Moore, (unknown), (unknown), James McCracken, David J. Cole, José A. Guevara-Patiño	7
17	NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses (52.12) 2011 ·The Journal of Immunology ·(unknown), Andrew Zloza, Gretchen E. Lyons, Frederick J. Kohlhapp, Jeremy A. O’Sullivan, (unknown), Emily Bellavance, Biljana Zafirova, Bojan Polić	1
18	Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+T cells and autoimmune vitiligo 2011 ·Autoimmunity ·Andrew Zloza, Gretchen E. Lyons, Lukasz K. Chlewicki, Frederick J. Kohlhapp, Jeremy A. O’Sullivan, (unknown), Tamson V. Moore, (unknown), Vinay Kumar, José A. Guevara-Patiño	18
19	Development of Tumor-Infiltrating CD8+ T Cell Memory Precursor Effector Cells and Antimelanoma Memory Responses Are the Result of Vaccination and TGF-β Blockade during the Perioperative Period of Tumor Resection 2011 ·The Journal of Immunology ·Emily Bellavance, Frederick J. Kohlhapp, Andrew Zloza, Jeremy A. O’Sullivan, James McCracken, (unknown), (unknown), Mitchell C. Posner, José A. Guevara-Patiño	17
20	CD8 Co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression 2010 ·Cancer Immunology Immunotherapy ·Andrew Zloza, (unknown), Gretchen E. Lyons, Michael C. Graves, Frederick J. Kohlhapp, Jeremy A. O’Sullivan, (unknown), Michael I. Nishimura, José A. Guevara-Patiño	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact